ProShare Advisors’s Inovio Pharmaceuticals INO Stock Holding History

ProShare Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,460	Closed	-$6.82K	–	1961
2023 Q3	$6.82K	Buy	1,460 +43	+3%	+$238	﹤0.01%	1813
2023 Q2	$7.59K	Sell	1,417 -2,449	-63%	-$19.7K	﹤0.01%	1847
2023 Q1	$38K	Sell	3,866 -504	-12%	-$8.59K	﹤0.01%	1698
2022 Q4	$81.8K	Buy	4,370 +351	+9%	+$7.96K	﹤0.01%	1685
2022 Q3	$83K	Buy	4,019 +475	+13%	+$12.2K	﹤0.01%	1594
2022 Q2	$74K	Sell	3,544 -1,501	-30%	-$42.3K	﹤0.01%	1656
2022 Q1	$217K	Sell	5,045 -1,188	-19%	-$53.5K	﹤0.01%	1839
2021 Q4	$373K	Buy	6,233 +280	+5%	+$22.4K	﹤0.01%	1650
2021 Q3	$511K	Sell	5,953 -1,652	-22%	-$166K	﹤0.01%	1205
2021 Q2	$846K	Buy	7,605 +1,098	+17%	+$105K	﹤0.01%	1132
2021 Q1	$725K	Buy	6,507 +1,401	+27%	+$184K	﹤0.01%	1191
2020 Q4	$542K	Buy	5,106 +1,255	+33%	+$167K	﹤0.01%	1222
2020 Q3	$536K	Buy	3,851 +120	+3%	+$25K	﹤0.01%	913
2020 Q2	$1.21M	Buy	3,731 +2,121	+132%	+$341K	0.01%	657
2020 Q1	$144K	Sell	1,610 -1,240	-44%	-$76.5K	﹤0.01%	1041
2019 Q4	$113K	Sell	2,850 -264	-8%	-$7.95K	﹤0.01%	1680
2019 Q3	$77K	Sell	3,114 -40	-1%	-$1.22K	﹤0.01%	1573
2019 Q2	$111K	Sell	3,154 -333	-10%	-$13.2K	﹤0.01%	1521
2019 Q1	$156K	Buy	3,487 +66	+2%	+$3.33K	﹤0.01%	1515
2018 Q4	$164K	Sell	3,421 -534	-14%	-$32.4K	﹤0.01%	1410
2018 Q3	$264K	Sell	3,955 -141	-3%	-$7.85K	﹤0.01%	1441
2018 Q2	$193K	Sell	4,096 -251	-6%	-$13.8K	﹤0.01%	1623
2018 Q1	$246K	Sell	4,347 -715	-14%	-$38.7K	﹤0.01%	1429
2017 Q4	$251K	Buy	5,062 +361	+8%	+$22.4K	﹤0.01%	1515
2017 Q3	$358K	Buy	4,701 +1,013	+27%	+$75.4K	﹤0.01%	1078
2017 Q2	$347K	Sell	3,688 -243	-6%	-$20.8K	﹤0.01%	1096
2017 Q1	$312K	Sell	3,931 -1,035	-21%	-$82.5K	﹤0.01%	1223
2016 Q4	$414K	Buy	4,966 +556	+13%	+$50.3K	﹤0.01%	1171
2016 Q3	$493K	Sell	4,410 -801	-15%	-$88.5K	0.01%	961
2016 Q2	$578K	Buy	5,211 +26	+0.5%	+$3.16K	0.01%	907
2016 Q1	$542K	Sell	5,185 -524	-9%	-$40.5K	0.01%	958
2015 Q4	$460K	Buy	5,709 +554	+11%	+$44.1K	0.01%	1070
2015 Q3	$358K	Sell	5,155 -382	-7%	-$33.3K	0.01%	1065
2015 Q2	$542K	Buy	5,537 +501	+10%	+$53.5K	0.01%	1067
2015 Q1	$493K	Buy	5,036 +618	+14%	+$59.9K	0.01%	1181
2014 Q4	$487K	Buy	4,418 +2,429	+122%	+$297K	0.01%	1211
2014 Q3	$235K	Sell	1,989 -451	-18%	-$56.2K	﹤0.01%	1873
2014 Q2	$316K	Buy	+2,440	New	+$288K	﹤0.01%	1870

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's INO Position: Q4 2023 in Review

ProShare Advisors sold out of Inovio Pharmaceuticals (INO) in Q4 2023, closing a stake of 1,460 shares — an estimated $6.82K sold.

ProShare Advisors first reported a position in INO in Q2 2014 and held it in 38 quarters. The position peaked at $1.21M in Q2 2020. 113 funds tracked by Wall St. Rank hold INO as of Q4 2023.

ProShare Advisors reported no remaining Inovio Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
ProShare Advisors sold 1,460 Inovio Pharmaceuticals shares in Q4 2023, an estimated $6.82K.
ProShare Advisors first reported a position in Inovio Pharmaceuticals in Q2 2014 and held it in 38 quarters.
ProShare Advisors's Inovio Pharmaceuticals position peaked at $1.21M in Q2 2020.
113 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2023.

Based on ProShare Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.